This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Attention-Deficit Hyperactivity Disorder (ADHD)
and you are
between 6 and 12
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.

Provided treatments

  • Drug: HLD100

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02884544. The sponsor of the trial is Ironshore Pharmaceuticals and Development, Inc and it is looking for 22 volunteers for the current phase.
Official trial title:
Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD